Sheaff Brock Investment Advisors, LLC Gilead Sciences, Inc. Transaction History

Sheaff Brock Investment Advisors, LLC

$1.13 Billion
Q3 2024

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 30, 2024	SELL	$63.15 - $72.88 $43,573 - $50,287	-690 Reduced 17.73%	3,201 $219,000
Q1 2024 May 14, 2024	SELL	$71.58 - $87.29 $14,316 - $17,458	-200 Reduced 4.89%	3,891 $285,000
Q4 2023 Feb 08, 2024	SELL	$73.27 - $83.09 $73,270 - $83,090	-1,000 Reduced 19.64%	4,091 $331,000
Q2 2023 Aug 08, 2023	BUY	$76.01 - $86.7 $1,900 - $2,167	25 Added 0.49%	5,091 $392,000
Q2 2022 Aug 02, 2022	SELL	$57.72 - $65.01 $23,088 - $26,004	-400 Reduced 7.32%	5,066 $313,000
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $316,590 - $396,722	5,466 New	5,466 $325,000
Q1 2022 May 06, 2022	SELL	$57.92 - $72.58 $333,850 - $418,351	-5,764 Closed	0 $0
Q4 2021 Jun 02, 2022	BUY	$64.88 - $73.64 $127,683 - $144,923	1,968 Added 51.84%	5,764 $419,000
Q4 2021 Feb 03, 2022	SELL	$64.88 - $73.64 $153,441 - $174,158	-2,365 Reduced 38.39%	3,796 $276,000
Q3 2021 Jun 02, 2022	BUY	$67.69 - $73.03 $146,548 - $158,109	2,165 Added 54.18%	6,161 $430,000
Q3 2021 Nov 03, 2021	SELL	$67.69 - $73.03 $159,883 - $172,496	-2,362 Reduced 37.15%	3,996 $279,000
Q2 2021 Jun 02, 2022	BUY	$63.47 - $69.35 $124,528 - $136,064	1,962 Added 44.63%	6,358 $438,000
Q2 2021 Aug 16, 2021	SELL	$63.47 - $69.35 $156,009 - $170,462	-2,458 Reduced 35.86%	4,396 $303,000
Q1 2021 Jun 02, 2022	BUY	$60.0 - $68.46 $87,480 - $99,814	1,458 Added 27.02%	6,854 $443,000
Q1 2021 May 11, 2021	SELL	$60.0 - $68.46 $208,200 - $237,556	-3,470 Reduced 39.14%	5,396 $349,000
Q4 2020 Feb 01, 2021	SELL	$56.65 - $64.55 $187,001 - $213,079	-3,301 Reduced 27.13%	8,866 $517,000
Q3 2020 Oct 30, 2020	BUY	$62.1 - $78.08 $100,291 - $126,099	1,615 Added 15.31%	12,167 $769,000
Q2 2020 Aug 07, 2020	SELL	$72.34 - $84.0 $17,216 - $19,992	-238 Reduced 2.21%	10,552 $812,000
Q1 2020 Apr 30, 2020	SELL	$62.63 - $80.22 $413,921 - $530,173	-6,609 Reduced 37.98%	10,790 $807,000
Q4 2019 Jan 29, 2020	SELL	$61.62 - $67.78 $150,907 - $165,993	-2,449 Reduced 12.34%	17,399 $1.13 Million
Q3 2019 Oct 28, 2019	SELL	$62.51 - $69.0 $158,525 - $174,984	-2,536 Reduced 11.33%	19,848 $1.26 Million
Q2 2019 Jul 31, 2019	SELL	$61.87 - $69.38 $66,448 - $74,514	-1,074 Reduced 4.58%	22,384 $1.51 Million
Q1 2019 Apr 29, 2019	SELL	$62.53 - $70.05 $215,353 - $241,252	-3,444 Reduced 12.8%	23,458 $1.53 Million
Q4 2018 Jan 28, 2019	BUY	$60.54 - $79.0 $112,725 - $147,098	1,862 Added 7.44%	26,902 $1.68 Million
Q3 2018 Nov 09, 2018	SELL	$71.28 - $78.92 $87,175 - $96,519	-1,223 Reduced 4.66%	25,040 $1.93 Million
Q2 2018 Jul 31, 2018	BUY	$64.88 - $75.68 $64,296 - $74,998	991 Added 3.92%	26,263 $1.86 Million
Q1 2018 May 03, 2018	SELL	$72.84 - $88.8 $130,602 - $159,218	-1,793 Reduced 6.62%	25,272 $1.91 Million
Q4 2017 Feb 12, 2018	SELL	$71.15 - $83.52 $195,733 - $229,763	-2,751 Reduced 9.23%	27,065 $1.94 Million
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $260,749 - $309,059	3,616 Added 13.8%	29,816 $2.42 Million
Q2 2017 Aug 09, 2017	BUY	N/A	26,200	26,200 $1.85 Million

Others Institutions Holding GILD

# of Institutions

1,926

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$10.7 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.2 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$6.77 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.46 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.32 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $111B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sheaff Brock Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sheaff Brock Investment Advisors, LLC with notifications on news.

Account